Lessons Learned from a Small Pediatric Continuous Renal Replacement Therapy Program

Table 2

Renal and continuous renal replacement metrics.

	Survivors (n = 51)	Nonsurvivors (n = 12)	value
Indications for CRRT^a			0.07
Renal failure	19 (37)	1 (8)
Sepsis	6 (12)	4 (33)
Nonseptic shock	5 (10)	4 (33)
Neonatal	5 (10)	1 (8)
Oncologic	6 (12)	2 (17)
Overdose	8 (16)	0
Other	2 (4)	0
Sepsis or nonsepsis shock diagnosis^a	11 (22)	8 (50)	0.004
Admission KDIGO score^a			0.52
0	8 (16)	0
1	5 (10)	1 (8)
2	18 (35)	5 (42)
3	20 (39)	6 (50)
Admission pRIFLE score^a			0.45
Normal	8 (16)	1 (8)
Risk	8 (16)	2 (17)
Injury	8 (16)	4 (33)
Failure	25 (49)	4 (33)
Loss	0 (0)	0 (0)
End stage	1 (2)	1 (8)
Creatinine, μmol/L^b
Hospital admission	397 (570)	295 (468.8)	0.58
PICU admission	394 (508)	300 (410)	0.55
Urea, mmol/L^b
Hospital admission	18.1 (16.8)	14.6 (14.2)	0.51
PICU admission	20.8 (15.7)	19.0 (14.4)	0.73
Urine output, ml/kg/hr^b
Hospital admission	0.79 (0.94)	0.58 (0.82)	0.47
PICU admission	1.34 (1.99)	1.22 (1.93)	0.76
Potassium, mmol/L^b
Hospital admission	4.8 (1.2)	4.8 (1.3)	0.94
PICU admission	4.7 (1.1)	4.6 (1.2)	0.85
Percent volume overload^b	7.4 (7.2)	12.0 (8.6)	0.06
Actual CRRT dose delivered/24-hour prescribed dose (ml/kg/hr)^b	0.85 (0.2)	0.95 (0.1)	0.15
UF removed 24 hr/UF prescribed 24 hr, %^b	1.3 (0.86)	1.5 (0.75)	0.47
24 hr time on CRRT, %^b	0.91 (0.1)	0.95 (0.04)	0.10
Citrate lock^a	18 (35)	3 (25)	0.74
Duration of CRRT, days^b	5.9 (5.1)	7.1 (6.7)	0.51
Time from PICU admission to CRRT initiation, days^b	1.1 (2.6)	5.0 (5.3)	0.0005

^aNumber (proportion); ^bmean (standard deviation). KDIGO: kidney disease improving global outcomes; pRIFLE: pediatric risk, injury, failure, loss, end stable renal disease; UF: ultrafiltrate.